Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced in vitro testing

References

• Neuhoff S, Ungell AL, Zamora I, et al. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003;20(8):1141–1148.
   PubMed Web of Science ®Google Scholar
• Koepsell H. Organic cation transporters in health and disease. Pharmacol Rev. 2020;72:253–319.
   PubMed Web of Science ®Google Scholar
• Pochini L, Galluccio M, Scalise M, et al. A small transporter subfamily with great relevance to human pathophysiology, drug discovery, and diagnostics. SLAS Discov. 2019;24(2): 89–110.
   PubMed Web of Science ®Google Scholar
• Wang J. The plasma membrane monoamine transporter (PMAT): structure, function, and role in organic cation disposition. Clin Pharmacol Ther. 2016;100(5):489–499.
   PubMed Web of Science ®Google Scholar
• Feng B, Varma MV. Evaluation and quantitative prediction of renal transporter-mediated drug-drug interactions. J Clin Pharmacol. 2016;56(Suppl 7):S110–121.
   PubMedGoogle Scholar
• Gessner A, König J, Fromm MF. Clinical aspects of transporter-mediated drug-drug interactions. Clin Pharmacol Ther. 2019;105(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Ivanyuk A, Livio F, Biollaz J, et al. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56:825–892.
   PubMed Web of Science ®Google Scholar
• Lepist EI, Ray AS. Renal drug-drug interactions: what we have learned and where we are going. Expert Opin Drug Metab Toxicol. 2012;8(4):433–448.
   PubMed Web of Science ®Google Scholar
• Lepist EI, Ray AS. Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins. Expert Opin Drug Metab Toxicol. 2017;13(10):1075–1087.
   PubMed Web of Science ®Google Scholar
• Stage TB, Brosen K, Christensen MM. A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet. 2015;54(8):811–824.
   PubMed Web of Science ®Google Scholar
• Koepsell H. Role of organic cation transporters in drug-drug interaction. Expert Opin Drug Metab Toxicol. 2015;11(10):1619–1633.
   PubMed Web of Science ®Google Scholar
• Neul C, Hofmann U, Schaeffeler E, et al. Characterization of CYP2D6 drugs as substrates of human organic cation transporters (OCTs) and multidrug and toxin extrusion proteins (MATEs). Br J Pharmacol. 2021;178(6):1459–1474.
   PubMed Web of Science ®Google Scholar
• Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem. 1998;273(32):20378–20382.
   PubMed Web of Science ®Google Scholar
• Gründemann D, Harlfinger S, Golz S, et al. Discovery of the ergothioneine transporter. Proc Natl Acad Sci U S A. 2005;102(14):5256–5261. .
   PubMed Web of Science ®Google Scholar
• Koepsell H. General overview of organic cation transporters in the brain. Handb Exp Pharmacol. 2021. 10.1007/164_2021_449.
   PubMedGoogle Scholar
• Koepsell H. Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol. 1998;60(1):243–266.
   PubMedGoogle Scholar
• Daws LC, Koek W, Mitchell NC. Revisiting serotonin reuptake inhibitors and the therapeutic potential of “uptake-2” in psychiatric disorders. ACS Chem Neurosci. 2013;4(1):16–21.
   PubMed Web of Science ®Google Scholar
• Geier EG, Chen EC, Webb A, et al. Profiling solute carrier transporters in the human blood-brain barrier. Clin Pharmacol Ther. 2013;94(6):636–639. .
   PubMed Web of Science ®Google Scholar
• Amphoux A, Vialou V, Drescher E, et al. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006;50(8):941–952. .
   PubMed Web of Science ®Google Scholar
• Courousse T, Gautron S. Role of organic cation transporters (OCTs) in the brain. Pharmacol Ther. 2015;146:94–103.
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50(4):1227–1240.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227–1251.
   PubMed Web of Science ®Google Scholar
• Duan H, Wang J. Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010;335(3):743–753.
   PubMed Web of Science ®Google Scholar
• Busch AE, Karbach U, Miska D, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998;54(2):342–352.
   PubMed Web of Science ®Google Scholar
• Bacq A, Balasse L, Biala G, et al. Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry. 2012;17(9):926–939.
   PubMed Web of Science ®Google Scholar
• Baganz NL, Horton RE, Calderon AS, et al. Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci USA. 2008;105(48):18976–18981.
   PubMed Web of Science ®Google Scholar
• Holleran KM, Rose JH, Fordahl SC, et al. Organic cation transporter 3 and the dopamine transporter differentially regulate catecholamine uptake in the basolateral amygdala and nucleus accumbens. Eur J Neurosci. 2020;52(11):4546–4562. .
   PubMed Web of Science ®Google Scholar
• Moon SJ, Oh J, Lee SH, et al. Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans. Transl Clin Pharmacol. 2018;26(2):79–85. .
   PubMedGoogle Scholar
• Tarasova L, Kalnina I, Geldnere K, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012;22(9):659–666.
   PubMed Web of Science ®Google Scholar
• Sundelin EI, Gormsen LC, Jensen JB, et al. Genetic polymorphisms in organic cation transporter 1 attenuates hepatic metformin exposure in humans. Clin Pharmacol Ther. 2017;102(5): 841–848.
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5): 1422–1431.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299–306. .
   PubMed Web of Science ®Google Scholar
• Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther. 2008;84(5):559–562.
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Yin OQ, Tomlinson B, et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637–645.
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86(4): 396–402. .
   PubMed Web of Science ®Google Scholar
• Iwata K, Aizawa K, Kamitsu S, et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol. 2012;16(6):843–851. .
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Saadatmand AR, Bokelmann K, et al. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. 2012;12(1): 22–29. .
   PubMed Web of Science ®Google Scholar
• Matthaei J, Kuron D, Faltraco F, et al. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016;99(6):633–641. .
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Matthaei J, Pojar S, et al. Increased systemic exposure and stronger cardiovascular and metabolic adverse reactions to fenoterol in individuals with heritable OCT1 deficiency. Clin Pharmacol Ther. 2018;103(5):868–878. .
   PubMed Web of Science ®Google Scholar
• Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56(9):1898–1906.
   PubMed Web of Science ®Google Scholar
• Shu W, Ma L, Hu X, et al. Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. Eur J Pharm Sci. 2020;142:105153.
   PubMed Web of Science ®Google Scholar
• Müller F, König J, Hoier E, et al. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 2013;86(6):808–815.
   PubMed Web of Science ®Google Scholar
• Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007;35(10):1956–1962.
   PubMed Web of Science ®Google Scholar
• Deutsch B, Neumeister C, Schwantes U, et al. Interplay of the organic cation transporters OCT1 and OCT2 with the apically localized export protein MATE1 for the polarized transport of trospium. Mol Pharm. 2019;16(2): 510–517.
   PubMed Web of Science ®Google Scholar
• Feng B, Obach RS, Burstein AH, et al. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther. 2008;83(4):567–576. .
   PubMed Web of Science ®Google Scholar
• Oefelein MG, Tong W, Kerr S, et al. Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults. Clin Drug Investig. 2013;33(2):123–131.
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008;83(2):273–280..
   PubMed Web of Science ®Google Scholar
• Christensen MMH, Hojlund K, Hother-Nielsen O, et al. Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol. 2015;71(6):691–697. .
   PubMed Web of Science ®Google Scholar
• Ito S, Kusuhara H, Yokochi M, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012;340(2):393–403. .
   PubMed Web of Science ®Google Scholar
• Lechner C, Ishiguro N, Fukuhara A, et al. Impact of experimental conditions on the evaluation of interactions between multidrug and toxin extrusion proteins and candidate drugs. Drug Metab Dispos. 2016;44(8): 1381–1389.
   PubMed Web of Science ®Google Scholar
• Zhou M, Engel K, Wang J. Evidence for significant contribution of a newly identified monoamine transporter (PMAT) to serotonin uptake in the human brain. Biochem Pharmacol. 2007;73(1):147–154.
   PubMed Web of Science ®Google Scholar
• Song IH, Zong J, Borland J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72(4):400–407. .
   PubMed Web of Science ®Google Scholar
• Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52(11):981–994.
   PubMed Web of Science ®Google Scholar
• Hibma JE, Zur AA, Castro RA, et al. The effect of famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacokinet. 2016;55(6):711–721.
   PubMed Web of Science ®Google Scholar
• Shibata M, Toyoshima J, Kaneko Y, et al. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers. Eur J Clin Pharmacol. 2020;76(8):1135–1141. .
   PubMed Web of Science ®Google Scholar
• Zack J, Berg J, Juan A, et al. Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus. Clin Pharmacol Drug Dev. 2015;4(2):121–129. .
   PubMed Web of Science ®Google Scholar
• Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469–491.
   PubMed Web of Science ®Google Scholar
• Müller F, Pontones CA, Renner B, et al. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction. Eur J Clin Pharmacol. 2015;71(1):85–94. .
   PubMed Web of Science ®Google Scholar
• Topletz-Erickson AR, Lee AJ, Mayor JG, et al. Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects. J Clin Pharmacol. 2020;61(4):461–471.
   PubMed Web of Science ®Google Scholar
• Shen H, Yang Z, Zhao W, et al. Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance. Drug Metab Dispos. 2013;41(12):2095–2103.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li S, Zhang Y, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011;33(3):315–327.
   PubMed Web of Science ®Google Scholar
• Sandoval PJ, Zorn KM, Clark AM, et al. Assessment of substrate-dependent ligand interactions at the organic cation transporter OCT2 using six model substrates. Mol Pharmacol. 2018;94(3): 1057–1068.
   PubMed Web of Science ®Google Scholar
• Zhu P, Ye Z, Guo D, et al. Irinotecan alters the disposition of morphine via inhibition of organic cation transporter 1 (OCT1) and 2 (OCT2). Pharm Res. 2018;35(12):243. .
   PubMed Web of Science ®Google Scholar
• Dujic T, Zhou K, Donnelly LA, et al. Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: aGoDARTS study. Diabetes. 2015;64(5):1786–1793. .
   PubMed Web of Science ®Google Scholar
• Cho SK, Kim CO, Park ES, et al. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers. Br J Clin Pharmacol. 2014;78(6):1426–1432.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Dos Santos Pereira JN, Meineke I, et al. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 2013;86(5):666–678. .
   PubMed Web of Science ®Google Scholar
• Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther. 2009;329(1):185–191.
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther. 2011;89(6): 837–844.
   PubMed Web of Science ®Google Scholar
• Johansson S, Read J, Oliver S, et al. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. Clin Pharmacokinet. 2014;53(9):837–847.
   PubMed Web of Science ®Google Scholar
• Grun B, Kiessling MK, Burhenne J, et al. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters. Br J Clin Pharmacol. 2013;76(5):787–796.
   PubMed Web of Science ®Google Scholar
• Sleijfer DT, Offerman JJG, Mulder NH, et al. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer. 1987;60(11):2823–2828. .
   PubMed Web of Science ®Google Scholar
• Li C, Li L, Yi Y, et al. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy. Biochem Pharmacol. 2020;177:114021.
   PubMed Web of Science ®Google Scholar
• Liao M, Jaw-Tsai S, Beltman J, et al. Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor. Xenobiotica. 2020;50(9):1032–1042. .
   PubMed Web of Science ®Google Scholar
• Seitz T, Stalmann R, Dalila N, et al. Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med. 2015;7(1):56.
   PubMed Web of Science ®Google Scholar
• Minuesa G, Volk C, Molina-Arcas M, et al. Transport of lamivudine [(-)-b-L-2´,3´-Dideoxy-3´-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009;329(1): 252–261.
   PubMed Web of Science ®Google Scholar
• Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther. 1996;59(5):550–558. .
   PubMed Web of Science ®Google Scholar
• Courousse T, Bacq A, Belzung C, et al. Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3beta signaling. Mol Psychiatry. 2015;20(7):889–900. .
   PubMed Web of Science ®Google Scholar
• Li ZH, Ma PK, Huang YF, et al. Jiaotai Pill (交泰丸) alleviates insomnia through regulating monoamine and organic cation transporters in rats. Chin J Integr Med. 2021;27(3):183–191.
   Web of Science ®Google Scholar
• Koepsell H. Multiple binding sites in organic cation transporters require sophisticated procedures to identify interactions of novel drugs. Biol Chem. 2019;400(2):195–207.
   PubMed Web of Science ®Google Scholar
• Popp C, Gorboulev V, Müller TD, et al. Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol. 2005;67(5): 1600–1611.
   PubMed Web of Science ®Google Scholar
• Gorbunov D, Gorboulev V, Shatskaya N, et al. High-affinity cation binding to organic cation transporter 1 induces movement of helix 11 and blocks transport after mutations in a modeled interaction domain between two helices. Mol Pharmacol. 2008;73(1): 50–61.
   PubMed Web of Science ®Google Scholar
• Keller T, Gorboulev V, Müller TD, et al. Rat organic cation transporter 1 contains three binding sites for substrate 1-methyl-4-phenylpyridinium per monomer. Mol Pharmacol. 2019;95(2): 169–182.
   PubMed Web of Science ®Google Scholar
• Volk C, Gorboulev V, Kotzsch A, et al. Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone. Mol Pharmacol. 2009;76(2): 275–289.
   PubMed Web of Science ®Google Scholar
• Schmitt BM, Koepsell H. Alkali cation binding and permeation in the rat organic cation transporter rOCT2. J Biol Chem. 2005;280(26):24481–24490.
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Rehman S, Albert CM, et al. Assay conditions influence affinities of rat organic cation transporter 1: analysis of mutagenesis in the modeled outward-facing cleft by measuring effects of substrates and inhibitors on initial uptake. Mol Pharmacol. 2018;93(4): 402–415.
   PubMed Web of Science ®Google Scholar
• Chen EC, Khuri N, Liang X, et al. Discovery of competitive and noncompetitive ligands of the organic cation transporter 1 (OCT1; SLC22A1). J Med Chem. 2017;60(7): 2685–2696.
   PubMed Web of Science ®Google Scholar
• Xu Y, Liu X, Li S, et al. Combinatorial pharmacophore modeling of organic cation transporter 2 (OCT2) inhibitors: insights into multiple inhibitory mechanisms. Mol Pharm. 2013;10(12):4611–4619.
   PubMedGoogle Scholar
• Belzer M, Morales M, Jagadish B, et al. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. J Pharmacol Exp Ther. 2013;346(2): 300–310.
   PubMed Web of Science ®Google Scholar
• Thevenod F, Ciarimboli G, Leistner M, et al. Substrate- and cell contact-Dependent inhibitor affinity of human organic cation transporter 2: studies with two classical organic cation substrates and the novel substrate Cd2+. Mol Pharm. 2013;10(8): 3045–3056.
   PubMedGoogle Scholar
• Nies AT, Koepsell H, Damme K, et al. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 2011;201:105–167.
   PubMedGoogle Scholar
• Yin J, Duan H, Wang J. Impact of substrate-dependent inhibition on renal organic cation transporters hOCT2 and hMATE1/2-K-mediated drug transport and intracellular accumulation. J Pharmacol Exp Ther. 2016;359(3):401–410.
   PubMed Web of Science ®Google Scholar
• Ahlin G, Karlsson J, Pedersen JM, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein. J Med Chem. 2008;51(19):5932–5942.
   PubMed Web of Science ®Google Scholar
• Wittwer MB, Zur AA, Khuri N, et al. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013;56(3):781–795.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski MJ, Taub ME, Chothe PP, et al. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. Clin Pharmacol Ther. 2018;104(5):890–899.
   PubMed Web of Science ®Google Scholar
• Hillgren KM, Keppler D, Zur AA, et al. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther. 2013;94(1):52–63. .
   PubMed Web of Science ®Google Scholar
• Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem. 2004;279(48):50042–50049.
   PubMed Web of Science ®Google Scholar
• Tatrai P, Schweigler P, Poller B, et al. A systematic in vitro investigation of the inhibitor preincubation effect on multiple classes of clinically relevant transporters. Drug Metab Dispos. 2019;47(7):768–778. .
   PubMed Web of Science ®Google Scholar
• He L, Wondisford FE. Metformin action: concentrations matter. Cell Metab. 2015;21(2):159–162.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ye J, Ganapathy V, et al. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci USA. 1999;96(5):2356–2360.
   PubMed Web of Science ®Google Scholar
• Gründemann D, Gorboulev V, Gambaryan S, et al. Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994;372(6506):549–552.
   PubMed Web of Science ®Google Scholar